Wells Fargo Upgrades Relay Therapeutics (RLAY) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts RLAY Hot Sheet
Price: $18.35 -5.75%
Rating Summary:
16 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
16 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Wells Fargo analyst Eva Fortea Verdejo upgraded Relay Therapeutics (NASDAQ: RLAY) from Equal Weight to Overweight with a price target of $13.00.
For an analyst ratings summary and ratings history on Relay Therapeutics click here. For more ratings news on Relay Therapeutics click here.
Shares of Relay Therapeutics closed at $7.79 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades Mondelez International (MDLZ) to Buy
- Prospect Ridge closes $1.84M critical metals flow-through placement
- Eureka Metals launches rights offering at $0.01 per share
Create E-mail Alert Related Categories
UpgradesRelated Entities
Wells Fargo, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
